Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series.

Détails

ID Serval
serval:BIB_769EFCFA5F42
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series.
Périodique
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Auteur(s)
Seçkin D., Barete S., Euvrard S., Francès C., Kanitakis J., Geusau A., Del Marmol V., Harwood C.A., Proby C.M., Ali I., Güleç A.T., Durukan E., Lebbé C., Alaibac M., Laffitte E., Cooper S., Bouwes Bavinck J.N., Murphy G.M., Ferrándiz C., Mørk C., Cetkovská P., Kempf W., Hofbauer G.F.
ISSN
1600-6143 (Electronic)
ISSN-L
1600-6135
Statut éditorial
Publié
Date de publication
2013
Volume
13
Numéro
8
Pages
2146-2153
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
Primary cutaneous posttransplant lymphoproliferative disorders (PTLD) are rare. This retrospective, multicenter study of 35 cases aimed to better describe this entity. Cases were (re)-classified according to the WHO-EORTC or the WHO 2008 classifications of lymphomas. Median interval between first transplantation and diagnosis was 85 months. Fifty-seven percent of patients had a kidney transplant. Twenty-four cases (68.6%) were classified as primary cutaneous T cell lymphoma (CTCL) and 11 (31.4%) as primary cutaneous B cell PTLD. Mycosis fungoides (MF) was the most common (50%) CTCL subtype. Ten (90.9%) cutaneous B cell PTLD cases were classified as EBV-associated B cell lymphoproliferations (including one plasmablastic lymphoma and one lymphomatoid granulomatosis) and one as diffuse large B cell lymphoma, other, that was EBV-negative. Sixteen (45.7%) patients died after a median follow-up of 19.5 months (11 [68.8%] with CTCL [6 of whom had CD30(+) lymphoproliferative disorders (LPD)] and 5 [31.2%] with cutaneous B cell PTLD. Median survival times for all patients, CTCL and cutaneous B cell PTLD subgroups were 93, 93, and 112 months, respectively. Survival rates for MF were higher than those for CD30(+) LPD. The spectrum of primary CTCL in organ transplant recipients (OTR) is similar to that in the general population. The prognosis of posttransplant primary cutaneous CD30(+) LPD is worse than posttransplant MF and than its counterpart in the immunocompetent population. EBV-associated cutaneous B cell LPD predominates in OTR.
Pubmed
Web of science
Open Access
Oui
Création de la notice
30/08/2013 17:10
Dernière modification de la notice
08/05/2019 20:34
Données d'usage